Menu Back toS11-How-Will-the-Development-and-NDA-Activities-in-Japan-Change-in-View-of-the-Future-of-AI-Translation
16th DIA Japan Annual Meeting 2019
[S11] How Will the Development and NDA Activities in Japan Change in View of the Future of AI Translation?
- Executive Officer, Division Vice president, Science & Data Technology Division
- AstraZeneca K.K., Japan
Following 2018 Japan annual meeting, the current status of AI translation in the pharmaceutical field will be reviewed. We will discuss how industrygovernment- academia collaboration should be promoted to further improve quality of AI translation, based on the status and issues of quality improvement before and after adaptation in pharmaceutical companies and success cases in other industries.
R&D Head Club's WGs report: Quality-improvement before and after Adaptation
Kiyoshi Kinoshita, PhD
- Manager, Regulatory Affairs, Area Japan Development
- MSD K.K., Japan
Key for Success of Machine Translation - How to Perform Post-Edit Effectively
- Medical Writer
- Novartis Pharma Co Ltd, Japan
A Case of Company-wide Introduction of AI Translation Technology -Background, Process and Future Prospects
- Manager, IT Strategy Department
- Daiichi Sankyo Co., Ltd, Japan